(Q42947484)

English

Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen

scientific article published on September 24, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Jean-Michel Molina

9

object named as

Jean-Michel Molina

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Constance Delaugerre

1

object named as

Constance Delaugerre

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

author name string

Isabelle Charreau

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Josephine Braun

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Marie-Laure Néré

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Nathalie de Castro

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Patrick Yeni

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Jade Ghosn

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Jean-Pierre Aboulker

8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

François Simon

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ANRS 138 study group

11

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

0 references

publication date

1 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

24 September 2010

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20683319

16 June 2024

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

2391-2395

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

1

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

2

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo

3

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro

4

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

5

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

6

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

7

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial

8

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01).

9

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Differences in proviral DNA load between HIV-1- and HIV-2-infected patients

10

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

11

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level

12

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load

13

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients

14

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells

15

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection.

16

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.

17

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life

18

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

19

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

20

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

21

1 reference

10.1097/QAD.0B013E32833D214C

https://api.crossref.org/works/10.1097/QAD.0B013E32833D214C

16 June 2024

Identifiers

10.1097/QAD.0B013E32833D214C

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

release_gulgiwvs25cung257t5iypp46q

1 reference

https://api.fatcat.wiki/v0/release/gulgiwvs25cung257t5iypp46q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42947484&oldid=2181170336"